Background Split-dose cisplatin plus gemcitabine is an alternative for combinations with
immunotherapy in unfit patients for full doses of cisplatin. The combination of split-dose …

Purpose Treatment targeting immune checkpoint with programmed death-1 (PD-
1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability …

Background The KEYNOTE-045 trial showed that pembrolizumab therapy improved the
survival of patients with advanced urothelial carcinoma (UC). However, its effectiveness in …

1. Sridhar SS, Blais N, Tran B, et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on
survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian …

Background/Aim: The optimal timing of switching from platinum-based chemotherapy to
pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear …

Objectives: Immune checkpoint inhibitor (ICI) is an important treatment option for metastatic
urothelial carcinoma (mUC) patients. A lot of clinical evidence proved the survival benefits of …

Background Cisplatin-based chemotherapy is the standard of care for first-line (1L)
metastatic urothelial carcinoma (mUC), although many patients (pts) are ineligible for …

Background This study aims to investigate the relationship between comorbidities and
survival in patients with mUC treated with pembrolizumab as a second-line treatment …

Background Urothelial carcinoma (UC) is the most common subtype of bladder cancer. The
randomized phase 3 KEYNOTE-045 trial showed that pembrolizumab, used as second-line …

Introduction Immunotherapy drug combinations (IO) have been increasingly utilized in first
line platinum ineligible and second line settings for locally advanced metastatic urothelial …